Haitian Creole
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
7 rezilta yo
Imidazole derivatives having affinity for .alpha.2 receptors
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
The present invention relates to substituted 4(5)-(1-indanyl and 1-indanylmethyl and 1-indanylmethylen)imidazoles and 4(5)-[1-(1,2,3,4-tetrahydronaphthyl and 1,2,3,4-tetrahydronaphthylmethyl and 1,2,3,4-tetrahydronaphthylmethylen]imidazoles and to their isomers, pharmaceutically acceptable salts and
Imidazole derivatives having affinity for alpha2 receptors
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
The present invention relates to substituted 4(5)-(1-indanyl and 1-indanylmethyl and 1-indanylmethylen)imidazoles and 4(5)-[1-(1,2,3,4-tetrahydronaphthyl and 1,2,3,4-tetrahydronaphthylmethyl and 1,2,3,4-tetrahydronaphthylmethylen]imidazoles and to their isomers, pharmaceutically acceptable salts and
Use of isatin derivatives as ion channel activating agents
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
TECHNICAL FIELD
The present invention relates to ion channel activating agents. More particularly, the present invention relates to a particular class of chemical compounds that has proven useful as openers of SK.sub.Ca and IK.sub.Ca channels. In further aspects, the present invention relates to the
A1 adenosine receptor antagonists
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
FIELD OF THE INVENTION
The present invention relates to compounds that are A.sub.1 adenosine receptor antagonists, and to their use in treating mammals for various disease states, such as asthma, diabetes, cardiac disorders, degenerative disorders of the central nervous system, and disease states
Adenosine A.sub.2B receptor agonists
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
The present invention relates to novel adenosine A.sub.2B receptor, agonists, pharmaceutical compositions containing them, and to methods of treating conditions and diseases mediated by the adenosine A.sub.2B receptor activity, by employing such compounds.
Accordingly, the present invention provides
Benzimidazolone derivatives as CB2 receptor ligands
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BACKGROUND OF THE INVENTION
This invention relates to benzimidazolone derivatives. These compounds have selective cannabinoid(CB)2 receptor binding activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives for the
Sulfonyl benzimidazole derivatives
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BACKGROUND OF THE INVENTION
This invention relates to sulfonyl benzimidazole derivatives. These compounds have selective cannabinoid (CB)2 receptor agonistic activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives
Baz done ki pi konplè remèd fèy medsin te apiye nan syans
- Travay nan 55 lang
- Geri èrbal te apiye nan syans
- Remèd fèy rekonesans pa imaj
- Kat entèaktif GPS - tag zèb sou kote (vini byento)
- Li piblikasyon syantifik ki gen rapò ak rechèch ou an
- Search remèd fèy medsin pa efè yo
- Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive
Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye
